284 related articles for article (PubMed ID: 12540024)
1. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head.
Crane CH; Antolak JA; Rosen II; Forster KM; Evans DB; Janjan NA; Charnsangavej C; Pisters PW; Lenzi R; Papagikos MA; Wolff RA
Int J Gastrointest Cancer; 2001; 30(3):123-32. PubMed ID: 12540024
[TBL] [Abstract][Full Text] [Related]
2. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Budiharto T; Haustermans K; Van Cutsem E; Van Steenbergen W; Topal B; Aerts R; Ectors N; Bielen D; Vanbeckevoort D; Goethals L; Verslype C
Radiat Oncol; 2008 Sep; 3():30. PubMed ID: 18808686
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
Pipas JM; Mitchell SE; Barth RJ; Vera-Gimon R; Rathmann J; Meyer LP; Wagman RS; Lewis LD; McDonnell C; Colacchio TA; Perez RP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1317-22. PubMed ID: 11483344
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
Ben-Josef E; Schipper M; Francis IR; Hadley S; Ten-Haken R; Lawrence T; Normolle D; Simeone DM; Sonnenday C; Abrams R; Leslie W; Khan G; Zalupski MM
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1166-71. PubMed ID: 22543215
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.
Allen AM; Zalupski MM; Robertson JM; Eckhauser FE; Simone D; Brown D; Hejna G; Normolle D; Lawrence TS; McGinn CJ
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1461-7. PubMed ID: 15275733
[TBL] [Abstract][Full Text] [Related]
6. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Ben-Josef E; Shields AF; Vaishampayan U; Vaitkevicius V; El-Rayes BF; McDermott P; Burmeister J; Bossenberger T; Philip PA
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):454-9. PubMed ID: 15145162
[TBL] [Abstract][Full Text] [Related]
7. Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
Yavuz AA; Aydin F; Yavuz MN; Ilis E; Ozdemir F
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):974-81. PubMed ID: 11704320
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.
McGinn CJ; Zalupski MM; Shureiqi I; Robertson JM; Eckhauser FE; Smith DC; Brown D; Hejna G; Strawderman M; Normolle D; Lawrence TS
J Clin Oncol; 2001 Nov; 19(22):4202-8. PubMed ID: 11709563
[TBL] [Abstract][Full Text] [Related]
9. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
Blackstock AW; Tepper JE; Niedwiecki D; Hollis DR; Mayer RJ; Tempero MA
Int J Gastrointest Cancer; 2003; 34(2-3):107-16. PubMed ID: 15361643
[TBL] [Abstract][Full Text] [Related]
10. Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study.
Bai YR; Wu GH; Guo WJ; Wu XD; Yao Y; Chen Y; Zhou RH; Lu DQ
World J Gastroenterol; 2003 Nov; 9(11):2561-4. PubMed ID: 14606097
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
Passoni P; Reni M; Cattaneo GM; Slim N; Cereda S; Balzano G; Castoldi R; Longobardi B; Bettinardi V; Gianolli L; Gusmini S; Staudacher C; Calandrino R; Di Muzio N
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1000-6. PubMed ID: 24267968
[TBL] [Abstract][Full Text] [Related]
12. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.
Konski A; Meyer JE; Joiner M; Hall MJ; Philip P; Shields A; McSpadden E; Choi M; Adaire B; Duncan G; Meropol NJ; Cescon TP; Cohen SJ
Radiother Oncol; 2014 Oct; 113(1):35-40. PubMed ID: 25441058
[TBL] [Abstract][Full Text] [Related]
13. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Kornek GV; Pötter R; Selzer E; Schratter A; Ulrich-Pur H; Rogy M; Kraus G; Scheithauer W
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):665-71. PubMed ID: 11172947
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of hypofractionated radiotherapy followed by systemic chemotherapy with full-dose gemcitabine in patients with unresectable locally advanced pancreatic cancer.
Furuse J; Ishii H; Kawashima M; Nagase M; Nihei K; Nakachi K; Ogino T; Yoshino M
Hepatogastroenterology; 2007; 54(77):1575-8. PubMed ID: 17708303
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Ikeda M; Okada S; Tokuuye K; Ueno H; Okusaka T
Br J Cancer; 2002 May; 86(10):1551-4. PubMed ID: 12085203
[TBL] [Abstract][Full Text] [Related]
16. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
Raftery L; Tepper JE; Goldberg RM; Blackstock AW; Aklilu M; Bernard SA; Ivanova A; Davies JM; O'Neil BH
Am J Clin Oncol; 2013 Jun; 36(3):250-3. PubMed ID: 22547007
[TBL] [Abstract][Full Text] [Related]
17. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
[TBL] [Abstract][Full Text] [Related]
18. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
Girard N; Mornex F; Bossard N; Ychou M; Chauffert B; Wautot V
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1426-32. PubMed ID: 20056351
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 Trial of Concurrent Gemcitabine and Cisplatin with Image Guided Intensity Modulated Radiation Therapy for Locoregionally Advanced Cervical Carcinoma.
Mell LK; Xu R; Yashar CM; McHale MT; Einck JP; Mayadev J; Lee E; Binder P; Rash D; Eskander R; Heide ES; Plaxe SC; Mundt AJ; Saenz CC
Int J Radiat Oncol Biol Phys; 2020 Aug; 107(5):964-973. PubMed ID: 32334034
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer.
Robertson JM; Margolis J; Jury RP; Balaraman S; Cotant MB; Ballouz S; Boxwala IG; Jaiyesimi IA; Nadeau L; Hardy-Carlson M; Marvin KS; Wallace M; Ye H
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e187-92. PubMed ID: 21549514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]